Literature DB >> 26253454

Blood transfusion does not affect survival of gastric cancer patients.

Jingli Cui1, Jingyu Deng1, Xuewei Ding1, Li Zhang1, Rupeng Zhang1, Weipeng Wu1, Xishan Hao1, Han Liang2.   

Abstract

BACKGROUND: To initially assess the impact of perioperative blood transfusions (PBTs) on overall survival of patients underwent curative resection of Ⅰ-Ⅲ TNM stage gastric cancer (GC) using the propensity scoring method.
METHODS: The medical records of 1150 GC patients who underwent curative resection in the Tianjin Cancer Hospital between 2003 and 2008 were retrospectively analyzed. Both transfusion and nontransfusion patients were assessed the prognostic differences after surgery using the propensity score analysis.
RESULTS: A total of 299 GC patients (26.0%) were administrated the PBT. With the unadjusted analysis, patients with PBT presented older age, more operative blood loss, lower hemoglobin, lower albumin level, and higher risk of the advanced disease. The 5-y survival rate for patients with PBT was 31.0%, which was significantly lower than that (47.9%) of patients without PBT (P < 0.05). However, we demonstrated that there was not any statistical 5-y survival rate difference of between patients with PBT and patients without PBT with the propensity score analysis (31.0% versus 31.3%, P > 0.05). In addition, we also found that PBT was not significantly associated with the increasing risk of mortality (hazard ratio, 1.054; P = 0.628).
CONCLUSIONS: PBT could not give rise to the worse prognoses of GC patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blood transfusion; Gastric cancer; Prognosis; Propensity score analysis

Mesh:

Year:  2015        PMID: 26253454     DOI: 10.1016/j.jss.2015.07.019

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

1.  Intraoperative blood loss does not independently affect the survival outcome of gastric cancer patients who underwent curative resection.

Authors:  B Zhao; X Huang; H Lu; J Zhang; R Luo; H Xu; B Huang
Journal:  Clin Transl Oncol       Date:  2019-01-28       Impact factor: 3.405

2.  Preoperative Anemia or Low Hemoglobin Predicts Poor Prognosis in Gastric Cancer Patients: A Meta-Analysis.

Authors:  Xuan-Zhang Huang; Yu-Chong Yang; You Chen; Cong-Cong Wu; Rui-Fang Lin; Zhen-Ning Wang; Xi Zhang
Journal:  Dis Markers       Date:  2019-01-02       Impact factor: 3.434

Review 3.  Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation.

Authors:  Masashi Ishikawa; Masae Iwasaki; Atsuhiro Sakamoto; Daqing Ma
Journal:  BMC Anesthesiol       Date:  2021-03-09       Impact factor: 2.217

Review 4.  Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis.

Authors:  Fausto Petrelli; Michele Ghidini; Antonio Ghidini; Giovanni Sgroi; Ivano Vavassori; Daniela Petrò; Mary Cabiddu; Alberto Aiolfi; Gianluca Bonitta; Alberto Zaniboni; Emanuele Rausa
Journal:  Surg Today       Date:  2021-01-03       Impact factor: 2.549

Review 5.  Optimal reconstruction methods after distal gastrectomy for gastric cancer: A systematic review and network meta-analysis.

Authors:  Zhaolun Cai; Ye Zhou; Chenxiao Wang; Yiqiong Yin; Yuan Yin; Chaoyong Shen; Xiaonan Yin; Zhixin Chen; Bo Zhang
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

6.  Peri-Operative Blood Transfusion Does Not Influence Overall and Disease-Free Survival After Radical Gastrectomy for Stage II/III Gastric Cancer: a Propensity Score Matching Analysis.

Authors:  Hua Xiao; Wu Liu; Hu Quan; Yongzhong Ouyang
Journal:  J Gastrointest Surg       Date:  2018-05-18       Impact factor: 3.452

7.  Preoperative Plasma Fibrinogen and Serum Albumin Score Is an Independent Prognostic Factor for Resectable Stage II-III Gastric Cancer.

Authors:  Menghui Wu; Yuchen Pan; Zhifang Jia; Yueqi Wang; Na Yang; Jianfeng Mu; Tianyu Zhou; Yaohua Guo; Jing Jiang; Xueyuan Cao
Journal:  Dis Markers       Date:  2019-10-29       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.